Synergy in St. Louis

Backers of a new cluster of business incubators in St. Louis hope to make America's heartland a hotbed of new life sciences companies. Five venture capital funds are now operating in an area where risk capital was once a rarity. Three have raised more than $60 million to invest in technology and life sciences firms; two more plan to raise another $300 million. "It's astounding when you think about it-five funds trying to raise money at the same time, when our kind of money is very scarce in th

Written byPeg Brickley
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

"It's astounding when you think about it-five funds trying to raise money at the same time, when our kind of money is very scarce in the Midwest," says Brian Clevinger, managing director of Prolog Ventures LLC, a venture capital firm set up to invest in companies nurtured by the St. Louis incubators. "The synergy here in St. Louis suggests we all believe that something amazing is going on." A few years back, few venture capitalists focused their radar screens on St. Louis, even though area employers spend $2 billion annually on research and development. But the Midwestern city has redrawn the venture capital map in recent years thanks in part to an old idea--business incubation.

Incubators encourage scientists to take their dreams to the market by providing them a hub of new facilities equipped with state-of-the-art research laboratories and networks of experts to help develop business models. Incubator organizers increasingly ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
July Digest 2025
July 2025, Issue 1

What Causes an Earworm?

Memory-enhancing neural networks may also drive involuntary musical loops in the brain.

View this Issue
Genome Modeling and Design: From the Molecular to Genome Scale

Genome Modeling and Design: From the Molecular to Genome Scale

Twist Bio 
Screening 3D Brain Cell Cultures for Drug Discovery

Screening 3D Brain Cell Cultures for Drug Discovery

Discover how to streamline tumor-infiltrating lymphocyte production.

Producing Tumor-infiltrating Lymphocyte Therapeutics

cytiva logo
Explore synthetic DNA’s many applications in cancer research

Weaving the Fabric of Cancer Research with Synthetic DNA

Twist Bio 

Products

The Scientist Placeholder Image

Sino Biological Sets New Industry Standard with ProPure Endotoxin-Free Proteins made in the USA

sartorius-logo

Introducing the iQue 5 HTS Platform: Empowering Scientists  with Unbeatable Speed and Flexibility for High Throughput Screening by Cytometry

parse_logo

Vanderbilt Selects Parse Biosciences GigaLab to Generate Atlas of Early Neutralizing Antibodies to Measles, Mumps, and Rubella

shiftbioscience

Shift Bioscience proposes improved ranking system for virtual cell models to accelerate gene target discovery